Halozyme Therapeutics (HALO) Return on Equity (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Return on Equity data on file, last reported at 0.03% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.03%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.03% (up 1.0% YoY), and the FY2025 annual result was 0.02%, changed 0.0% from the prior year.
• Return on Equity rose to 0.03% in Q1 2026 per HALO's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.03% in Q1 2026 and troughed at 0.01% in Q3 2024.
• A 5-year average of 0.02% and a median of 0.01% in 2025 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2022 and 2023: Return on Equity decreased 1 bps in 2022, then rose 1 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then advanced by 12 bps to 0.02% in 2023, then tumbled by 36 bps to 0.01% in 2024, then climbed by 5 bps to 0.01% in 2025, then jumped by 127 bps to 0.03% in 2026.
• Business Quant data shows HALO's Return on Equity at 0.03% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.